• Latest Posts
In Depth 16 Nov 2023

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

In Depth 15 Nov 2023

Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy

In Depth 9 Nov 2023

Blood tests for Alzheimer’s: a hit or a miss?

In Depth 8 Nov 2023

Promising cure for COPD: is a breakthrough treatment within reach?

In Depth 6 Nov 2023

The biggest private biotech investments in October 2023

In Depth 2 Nov 2023

How French pharma giant Sanofi is betting big on AI

In Depth 30 Oct 2023

The ongoing search for an HIV cure: can CRISPR crack the code?

In Depth 27 Oct 2023

Big pharma monopolies: major antitrust cases over the past decade

In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

In Depth 20 Oct 2023

Is Africa ready to become the next big biopharma and vaccine manufacturing destination?

In Depth 19 Oct 2023

Biotech’s battle against NASH: The ongoing pursuit of an effective treatment

In Depth 18 Oct 2023

Going nuclear: radiopharmaceuticals see surge in funding